Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response to standard-dose granulocyte colony-stimulating factor (G-CSF), defined by <2 × 10(6) CD34 + cells/kg recipien...

Descripción completa

Detalles Bibliográficos
Autores principales: Hölig, Kristina, Schmidt, Helmuth, Hütter, Gero, Kramer, Michael, Teipel, Raphael, Heidrich, Katharina, Zimmer, Kristin, Heidenreich, Falk, Blechschmidt, Matthias, Torosian, Tigran, Ordemann, Rainer, Kroschinsky, Frank, Rücker-Braun, Elke, Gopsca, Laszlo, Wagner-Drouet, Eva Maria, Oelschlaegel, Uta, Schmidt, Alexander H., Bornhäuser, Martin, Ehninger, Gerhard, Schetelig, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589660/
https://www.ncbi.nlm.nih.gov/pubmed/33028987
http://dx.doi.org/10.1038/s41409-020-01053-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589660/
https://www.ncbi.nlm.nih.gov/pubmed/33028987
http://dx.doi.org/10.1038/s41409-020-01053-4

Ejemplares similares